tbuckley/cabot-search huggingface dataset:
Abstract P325: The Prognostic Utility of Vitamin D and Its Seasonal Variation in Chest Pain Patients with Suspected Acute Coronary Syndrome Recruited from a Coastal Population in Western-Norway
Authors: Patrycja A Naesgaard, Volker Pönitz, Trygve Brúgger-Andersen, Hildegunn Aarsetoey, Heidi Grundt, Cato Brede, Harry Staines, Dennis W Nilsen
Journal: Circulation (2012)

Background: Several studies have shown a correlation between low vitamin D levels and cardiovascular risk. Serum concentration of 25-hydroxy-vitamin D (25(OH)D) is an established marker of vitamin D status. The purpose of this study was to assess the prognostic utility of 25(OH)D status in 871 chest-pain patients with suspected acute coronary syndrome (ACS) from Western-Norway. Methods: Serum samples for determination of 25(OH)D were obtained at admission. Baseline data consisted of serum levels of Troponin T (TnT), high sensitive C-reactive protein, creatinine, glucose, lipids and B-type natriuretic peptide measured in EDTA plasma, as well as clinical parameters, including age, gender, previous MI, angina pectoris, previous revascularizations (percutaneous coronary intervention or coronary artery bypass graft), congestive heart failure, diabetes mellitus, smoking status, hypercholesterolemia (total cholesterol &gt; 250 mg/dl or statin treated hypercholesterolemia), beta-blocker prior to enrolment, hypertension, body mass index and seasons (defined as November through April and May through October). The main endpoint was total mortality in the total population and in the TnT positive group (TnT &gt; 0.01 ng/mL). Multivariate analysis was performed in 794 patients with a complete set of baseline variables. Results: The mean age was 69.6 and 39% were females. After 24 months follow-up, 136 patients had died. The mean vitamin D value was 53.8 nM (95% CI, 52.2 nM - 55.4 nM) between November 2002 and April 2003, and 50.2 nM (95%CI, 48.1 nM - 52.3 nM) between May 2003 and October 2003; p = 0.008. In the univariate analysis of all cause mortality in the total population, the hazard ratio (HR) for 25(OH)D in the highest quartile as compared to the lowest quartile was 0.63 (95% confidence interval (CI), 0.38 - 1.03), p = 0.065, and in the TnT positive patients the HR was 0.58 (95% CI, 0.33 - 1.03), p = 0.062. No difference in mortality was found between the vitamin D quartiles in the TnT negative population. The results remained statistically non-significant in the multivariate analysis. Conclusion: In an univariate analysis there was a trend towards higher mortality in the lowest quartile of vitamin D as compared to the highest quartile in our chest pain population with suspected ACS. Furthermore, there was a statistically significant seasonal difference in vitamin D levels.
Abstract 368: Inferred regulatory interaction network from prostate cancer reveals potential regulators coordinating progression and metastasis
Authors: Xudong Dai, Yixuang Gong, Matthew D. Galsky, Eric E. Schadt, William K. Oh, Jun Zhu
Journal: Cancer Research (2014)

Abstract Introduction: Significant genomic reprogramming occurs when prostate cancer cells acquire androgen receptor (AR) independent growth and metastasize to remote sites. Recent whole genome sequencing studies have noted recurrent gene deletion, amplification, fusion and widespread chromoplexy associated with prostate cancer progression. Synchronizing such a multistep multicomponent process, involving both cancer cells and tumor microenvironment, to gain growth advantage is challenging without a master coordinator. Genome-wide siRNA screenings have been undertaken to identify regulators driving such a reprogramming process affecting cancer cell themselves, but not the necessary interaction with host tissue. Thereby a novel approach was developed in the current work to uncover potential regulators that coordinate major cancer hallmarks and tumor-host interactions leading to prostate cancer progression. Methods: A network of potential regulatory interactions among genes was derived from matched prostate cancer expression profiles and copy number variation (CNV) datasets. The relevance of the inferred network was examined by experimentally derived AR target networks and literature mining- based cancer gene interaction networks. Subsequently, a network topology-based matrix, critical node index, was established to identify network modules significantly associated with biochemical recurrence—a clinical surrogate marker representing prostate cancer progression. Results: When bench-marked with established prostate cancer gene sets, the critical node downstream modules were more significantly enriched for individual genes with strong prognostic power (P&amp;lt;1E-5). Furthermore, compounds, which are capable of reversing expression patterns of individual top critical node downstream modules, either inhibited cancer cell growth or tumor progression in public datasets and literature. More importantly, overexpression or knock down of individual critical nodes in LNCaP, 22RV1, and PC3 prostate cancer cell lines demonstrated the potential of critical nodes to coordinate AR-independent growth through regulating host tissue immune interactions. Conclusion: Our preliminary results imply the existence of network modules that can synchronize the effects of genomic reprogramming during prostate cancer progression and metastasis. Note: This abstract was not presented at the meeting. Citation Format: Xudong Dai, Yixuang Gong, Matthew D. Galsky, Eric E. Schadt, William K. Oh, Jun Zhu. Inferred regulatory interaction network from prostate cancer reveals potential regulators coordinating progression and metastasis. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 368. doi:10.1158/1538-7445.AM2014-368
Abstract P4-02-10: Detection of H1047R and E545K PIK3CA mutations from peripheral blood in ER positive breast cancer patients
Authors: Jose Angel Garcia-Saenz, Daniel Acosta, Fernando Moreno, Paticia Ayllon, Miguel Sotelo, Trinidad Caldes, Eduardo Diaz-Rubio, Atocha Romero
Journal: Cancer Research (2015)

Abstract Background: Digital polymerase chain reaction (PCR) is a new technology that enables detection and quantification of cancer DNA molecules from peripheral blood. Detecting tumor-specific mutations in circulating plasma DNA may potentially be useful to select systemic therapies for solid tumors. The aim of our study is to evaluate the feasibility of detecting PIK3CA mutations from plasma of breast cancer patients. Methods: We have designed an allele-specific PCR assay and used a digital PCR system for the detection of PIK3CA mutations H1047R and E545K. Formalin-fixed paraffin-embedded (FFPE) tumor samples were analyzed by COBAS and by digital PCR. The matched plasma samples were then analyzed by digital PCR. Kappa Cohen’s coefficient (κ) was used to test agreement between methods Results: 37 ER positive breast cancer and matched plasma were evaluated. 31 (84%) patients were stage IV disease. E545K mutation was detected in 4 out of 37 (11%) tumor specimens and H1047R mutation was identified in 8 out of 37 (22%) tumor samples. The proportion of observed agreement between H1047R and E545K detection in tumor samples by COBAS and digital PCR was 100%. Regarding E545K mutation assay we found that the proportion of observed agreement between mutation status in FFPE samples and circulating tumor DNA (ctDNA) was 94.6% (kappa= 0.770; Sensitivity=100%; Specificity=93.9%). In H1047R assay the proportion of observed agreement between FFPE samples and ctDNA was 83.78% (Kappa=0.561; Sensitivity=60%; Specificity=92.59%). Conclusions: The agreement between methodologies when assessing the PIK3CA status in tumor samples was perfect. However, a moderate-to-fair agreement was found between FFPE samples and ctDNA which might be due to the heterogeneity of the disease. The methodology presented in this study is a feasible approach for PIK3CA mutation detection in blood derived samples. Citation Format: Jose Angel Garcia-Saenz, Daniel Acosta, Fernando Moreno, Paticia Ayllon, Miguel Sotelo, Trinidad Caldes, Eduardo Diaz-Rubio, Atocha Romero. Detection of H1047R and E545K PIK3CA mutations from peripheral blood in ER positive breast cancer patients [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P4-02-10.
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer
Authors: Raquel Pascual Cascon, Samantha Aso González, Mariana Muñoz Esquerre, José Ignacio Martínez Ballarin, Susana Padrones Sancez, Ivan Macia Vidueira, Francisco Rivas Doyague, Felipe Cardenal Alemany, Maria Dolores Arnaiz Fernandez, Sergio Morchon Ramos, Jordi Dorca Sargatal
Journal: European Respiratory Journal (2011)

Background and aim:  Surgery is the treatment of choice in early stage non small cell lung cancer (NSCLC). It is also used in some cases of locally advanced tumors, but with a low cure rate. Therefore, preoperative treatment is seeking to improve survival in these patients. The aim of this study was to evaluate tumor resectability and survival in patients with locally advanced stage (IIIA and IIIB) NSCLC treated with chemotherapy (CT) or chemotherapy and radiotherapy (CT-RT) neoadjuvant   Methods:  This was a restrospective study that evaluated patients with locally advanced NSCLC in a university hospital during 2000-2006, that received induction therapy. The collected variables were anthropometric values, histology, stage of the tumor, neoadjuvant treatment and therapeutic response. Kaplan-Meier curve was used to evaluate survival and analysis of variance to compare values among groups.   Results:  32 patients were included; 9 subjects (28%) were diagnosed with stage IIIA and 23 (72%) stage IIIB, being the IIIB the most common indication for induction therapy. All patients were treated with CT, showing a treatment response in 80% of cases and only 7 were also required RT. Resection was indicated in 31 patients and only in 6 subjects exploratory thoracotomy was performed, seeing a downstaging in 46.9% of all the cases. Over-all 5 year survival was 27.8% with a median of 52.9 months (95% CI 38.1-67.6). This survival is dependent on the response to neoadjuvant.   Conclusions:  Neoadjuvant reduces tumor size resulting in a downstaging and improving the resectability of locally advanced NSCLC. It could be a viable therapeutic option to improve survival of these patients.
Abstract 906: KIF6 Genetic Variant Predicts Effect of Intensive Statin Therapy on Death and Cardiovascular Events in the PROVE IT-TIMI 22 Trial
Authors: Marc S Sabatine, Olga A Iakoubova, Charles M Rowland, Carmen Tong, Joseph J Catanese, Christopher P Cannon, James J Devlin, Eugene Braunwald
Journal: Circulation (2007)

BACKGROUND: Genetic diversity can result in differential risk of disease and differential response to therapy in patients. The 719Arg variant of kinesin-like protein 6 (KIF6, a member of a family o...
Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma
Authors: Arnold S. Freedman, Donna Neuberg, Peter Mauch, Robert J. Soiffer, Kenneth C. Anderson, David C. Fisher, Robert Schlossman, Edwin P. Alyea, Tak Takvorian, Haddy Jallow, Caroline Kuhlman, Jerome Ritz, Lee M. Nadler, John G. Gribben
Journal: Blood (1999)
The Pharmacologic Principles of Medical Practice: A Textbook on Pharmacology and Therapeutics for Medical Students, Physicians, and the Members of the Professions Allied to Medicine
Authors: John Christian Krantz, C. Jelleff Carr
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PENICILLIN AND PENICILLIN-MALARIA IN THE TREATMENT OF TABES DORSALIS
Authors: H PACKER, Y T WONG
Journal: Annals of Internal Medicine (1949)

Article1 July 1949PENICILLIN AND PENICILLIN-MALARIA IN THE TREATMENT OF TABES DORSALISHENRY PACKER, M.D., F.A.C.P., Y. T. WONG, M.D.HENRY PACKER, M.D., F.A.C.P., Y. T. WONG, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-31-1-96 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe demonstration of favorable results with the use of penicillin in the treatment of tabes dorsalis, shortly after the introduction of this drug in the treatment of syphilis, was of special interest, in view of the highly complex and uncertain origin of the clinical manifestations of this disease. Stokes et al.1reported in 1944 that improvement in lightning pains following treatment with penicillin occurred in four of seven patients with this symptom. Subsequently Gammon et al.2reporting on a larger series, found that 66 per cent of tabetic patients with abnormal spinal fluids showed improvement in spinal fluid following penicillin...Bibliography1. STOKESSTERNBERGSCHWARTZMAHONEYMOOREWOOD JHTHWHJFJEWB: The action of penicillin in late syphilis, Jr. Am. Med. Assoc., 1944, cxxvi, 73-79. CrossrefGoogle Scholar2. GAMMONSTOKESBEERMANINGRAHAMLENTZMORGANSTEELEROSE GDJHHNRJWHGWEK: Penicillin in neurosyphilis, Jr. Am. Med. Assoc., 1945, cxxviii, 653-654. CrossrefGoogle Scholar3. O'LEARYBRUNSTINGOCKNLY PALAO: Penicillin in the treatment of neurosyphilis, Jr. Am. Med. Assoc., 1946, cxxx, 698-700. CrossrefGoogle Scholar4. STOKESSTEIGERGAMMONSTEELEBEERMANINGRAHAMGYORGYROSELENTZ JHHPGDWHHNRPEKJW: Penicillin alone in neurosyphilis, Jr. Am. Med. Assoc., 1946, cxxxi, 1-7. Google Scholar5. KOTEENDOTYWEBSTERMCDERMOTT HEJBW: Penicillin therapy in neurosyphilis, Am. Jr. Syph., Gonor. and Ven. Dis., 1947, xxxi, 1-13. Google Scholar6. WONGPACKER YTH: Penicillin and penicillin-malaria in the treatment of neurosyphilis, Am. Jr. Syph., Gonor. and Ven. Dis. In press. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Memphis, Tennessee*Received for publication January 22, 1948.The work described in this paper was initiated under a contract between the Office of Scientific Research and Development and the University of Tennessee, and completed under a grant from the United States Public Health Service.From the Division of Preventive Medicine and the Department of Psychiatry, University of Tennessee College of Medicine, Memphis. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byEXPERIENCES WITH A FOLLOW-UP EXAMINATION OF 200 TABETIC PATIENTSSyphilis 1 July 1949Volume 31, Issue 1Page: 96-104KeywordsDrugsMedical servicesPenicillinPreventive medicineSyphilis ePublished: 1 December 2008 Issue Published: 1 July 1949 PDF downloadLoading ...
Abstract 829: The novel camptothecin derivative and IAP inhibitor FL118 is an effective treatment for irinotecan-refractory colorectal cancer
Authors: David Westover, Xiang Ling, Xiaojun Liu, Hong Lam, Celine Gongora, Maguy Del Rio, Fengzhi Li
Journal: Cancer Research (2014)

Abstract The current standard care for metastatic colorectal cancer is combination of leucovorin, 5-fluorouracil, and irinotecan. Irinotecan is a semisynthetic analogue of the alkaloid camptothecin and functions by inducing DNA double-strand breaks through inhibition of topoisomerase I (Top1) activity. The camptothecin-derived Top1 inhibitors irinotecan and topotecan are effective anti-cancer agents that are currently utilized as first-line therapies in several human cancers. Unfortunately, resistance to these agents usually develops during treatment, often through upregulation of the drug efflux pump ABCG2, an ATP-binding cassette transporter. By increasing the rate of drug export, ABCG2 decreases the amount of irinotecan or topotecan that accumulates intracellularly, thereby protecting cancer cells from the cytotoxic effects of these drugs. Therefore, a camptothecin derivative that is also a poor substrate for ABCG2 could potentially overcome ABCG2-induced irinotecan resistance and restore therapeutic efficacy. Our lab recently reported on a novel camptothecin derivative, FL118, which shows strong anti-cancer activity both in vitro and in vivo. Here we report the ability of FL118 to overcome irinotecan resistance. Several irinotecan-resistant colon cancer cell lines derived from HCT116 were treated with either FL118 or SN38, the active metabolite of irinotecan. We observed a decrease in the potency of SN38 in irinotecan-resistant cells that overexpressed ABCG2 compared to cells that did not overexpress ABCG2. In contrast, this loss of potency was not observed for FL118. To confirm that the decrease in potency was ABCG2-dependent, HCT116-A2, an ABCG2 overexpressing cell line, was treated with SN38 or FL118 in the presence or absence of Ko143, an ABCG2 inhibitor. We observed that Ko143 could restore potency to SN38 in HCT116-A2 cells, confirming that irinotecan resistance in HCT116-A2 cells is mediated by ABCG2. However, Ko143 could not modulate the potency of FL118, further suggesting that FL118 is not affected by ABCG2 activity. Similar results were observed in studies with anti-ABCG2 shRNA. Based on these observations, we conclude that FL118 is not a substrate for ABCG2, and that further testing is warranted to determine whether FL118 would be an effective anti-cancer agent for patients with irinotecan-resistant colorectal cancer overexpressing ABCG2. Citation Format: David Westover, Xiang Ling, Xiaojun Liu, Hong Lam, Celine Gongora, Maguy Del Rio, Fengzhi Li. The novel camptothecin derivative and IAP inhibitor FL118 is an effective treatment for irinotecan-refractory colorectal cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 829. doi:10.1158/1538-7445.AM2014-829
Abstract P037: 24-hour Urinary Amino Acid Excretion And Blood Pressure: The Intermap Study
Authors: Martha L Daviglus, Jeremiah Stamler, Queenie Chan, Ian J Brown, Alan R Dyer, Daniel B Garside, Xuan Cai, Katsuyuki Miura, Hirotsugu Ueshima, Liancheng Zhao, Paul Elliott
Journal: Circulation (2014)

Background: Available data indicate inverse relations to blood pressure (BP) of dietary vegetable protein and its main amino acid, glutamic acid, also direct relations to BP of meat and animal protein intakes. Data on association of urinary amino acids (UAAs) with BP are limited. Objective: To assess the relationship between UAAs and BP. Methods: This study assessed relations to BP of 21 urinary amino acids among 4,677 men and women ages 40-59 (17 population samples in China, Japan, UK, USA) from the International Study on Macro/Micronutrients and Blood Pressure (INTERMAP). Urinary amino acid excretion was expressed as log transformed value of each urinary amino acid (μmol/24 h), and as % dietary total protein (based on urinary urea nitrogen excretion). Results: In multivariate analyses with all 21 UAAs considered together, independent inverse relations to BP were found for serine, glycine, and lysine, and independent direct relations to BP for threonine, cystine, and 3-methylhistidine, controlling for possible non-dietary and dietary confounders (including body mass index and each of the other UAAs). For example, with log urinary serine at 75th compared to the 25th percentile, SBP/DBP was lower by 2.4/1.8 mm Hg and 2.2/1.7 mm Hg on average without and with adjustment for body mass index in multivariate models. With log urinary 3-methylhistidine at 75th compared to the 25th percentile, SBP/DBP was higher by 3.8/2.7 and 1.6/1.4 mm Hg. Conclusions: These significant new findings on relations to blood pressure of urinary amino acids need to be verified by additional - including prospective - data.
Drug points: Worsening of symptoms of multiple sclerosis associated with carbamazepine
Authors: G Ramsaransing, C Zwanikken, J De Keyser
Journal: BMJ (2000)

Carbamazepine is widely used to treat paroxysmal neurological symptoms and pain.We report on five patients with multiple sclerosis in whom disability was seriously enhanced by treatment with carbamazepine at comparatively low dosages.It is possible to misinterpret worsening of symptoms as an exacerbation of multiple sclerosis.
Abstract 569: NT-proBNP is an Important Independent Predictor of Clinical Events after Primary PCI for STEMI
Authors: Justin A Ezekowitz, Jeffery A Bakal, Kurt Huber, Pierre Theroux, Stefan K James, Amadeo Betriu, W. Douglas Weaver, Christopher B Granger, Paul W Armstrong
Journal: Circulation (2008)

Acute myocardial infarction with ST-segment elevation (STEMI) remains a major global public health issue. Despite advances in therapy, patients remain at risk for death, repeat myocardial infarction (MI) shock and heart failure (HF). Novel markers that predict those at risk are needed. We studied 903 STEMI patients in The Assessment of Pexelizumab in Acute Myocardial Infarction trial (which enrolled STEMI patients presenting &lt; 6 hrs of symptom onset who were to undergo primary PCI) in a case-control design (cases selected based on the trial’s primary composite outcome - death, shock or HF - and matched on age, gender and infarct location to controls). NT-proBNP (pg/ml) was measured at randomization and 24 hrs. Outcomes (individually and the composite) of death, shock, and HF at 90 days were examined by quartiles of NT-proBNP. A CART model was used to categorize adjusted risk. NT-proBNP was higher in patients who had events. Patients with higher NT-proBNP levels at baseline (median symptom onset to randomization 2.7 hrs) and 24 hrs had more events (composite p&lt;0.001; death p&lt;0.0001; HF p&lt;0.0001; shock p=0.05) - See figure . Using the CART model (adjusted for age, gender and infarct location), baseline Killip class and NT-proBNP could further subcategorize patients into 90 day mortality categories 4%, 10%, 30%, and 53%. In fact, only 4 patients (1%) with a 24 hour NT-proBNP &lt;999 pg/ml had any event in the next 90 days. Although the overall prognosis in STEMI patients undergoing primary PCI is good, NT-proBNP performed early and at 24 hrs provides important prognostic information for predicting negative outcomes i.e. shock, heart failure and death. Figure. Kaplan-Meier curve for the primary composite outcome stratified by baseline NT-proBNP (a), or 24 hour NT-proBNP (b).